INKT

MiNK Therapeutics, Inc.

Biological Products, (No Diagnostic Substances)Nasdaq<br>Emerging growth company

Total Trades

10

Buys

8

Sells

2

Largest Trade

$100K–$500K

Insiders

4

Institutional Funds

20

Inst. Value

$1M+

Activist Filings

5

Insider Trades

InsiderTitleTypeValueSharesPriceDate
Ryan BarbaraDirectorSELL$1K–$15K500$10.85Mar 4, 2026
AGENUS INC10% OwnerBUY$15K–$50K23K$1.10Oct 16, 2023
AGENUS INC10% OwnerBUY$15K–$50K15K$1.09Oct 6, 2023
AGENUS INC10% OwnerBUY$15K–$50K30K$1.52Aug 31, 2023
AGENUS INC10% OwnerBUY$100K–$500K183K$1.54Aug 28, 2023
AGENUS INC10% OwnerBUY$50K–$100K45K$1.47May 12, 2023
ARMEN GARO HDirectorSELL$50K–$100K100K$0.95May 5, 2023
AGENUS INC10% OwnerBUY$100K–$500K250K$1.04May 5, 2023
ARMEN GARO HDirectorBUY$50K–$100K100K$0.95May 4, 2023
WIINBERG ULFDirectorBUY$15K–$50K20K$1.38Jul 21, 2022
🔓Seeing ranges? Sign in for exact trade values — free forever

Institutional Ownership

13F filings as of Dec 31, 2025 · 20 funds holding

Activist & 5%+ Owners

SC 13D/13G filings — investors holding 5%+ of outstanding shares

GKCC, LLC

SC 13G · May 22, 2024

11.8%

4.6M shares

Garo H. Armen 2.

SC 13D · Feb 14, 2024

351.4M shares

Agenus Inc. (“Agenus”)

SC 13D/A · May 26, 2023

62.5%

21.5M shares

Agenus Inc. (“Agenus”)

SC 13D/A · May 3, 2023

62.0%

21.3M shares

Garo H. Armen

SC 13G · Feb 14, 2022

7.8%

2.6M shares

View on Google Finance →